(AVDL) – Hot FDA News
-
Avadel Pharma (AVDL) Announces Favorable Ruling on Motion to Delist REMS Patent from FDA’s Orange Book
-
Avadel Pharma (AVDL) Phase 3 REST-ON Trial of Once-Nightly FT218 for Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy Met Endpoints
Back to AVDL Stock Lookup